Executive Summary
Intas Pharmaceuticals successfully secured the institution of IPR against Atossa Therapeutics over a drug polymorph patent (11,261,151), challenging claims based on anticipation and obviousness using prior art Liu.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Intas Pharmaceuticals, Ltd. et al. vs Atossa Therapeutics, Inc. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
CISCO SYSTEMS, INC.vsUMBRA TECHNOLOGIES LTD.
CISCO SYSTEMS, INC. successfully petitioned the PTAB to institute an IPR against UMBRA TECHNOLOGIES LTD.'s patent 11108595. The Board found the petition particularly strong on the merits and favorable regarding Fintiv factors.
Comcast Corporation et al.vsEntropic Communications LLC
Comcast Cable Communications challenged Entropic's patent (11,381,866) in an IPR proceeding, asserting that the claims are obvious over various combinations of prior art. The petitioner relies heavily on combining Cholas and Petrovic with references like Rabaey, Maalej, Lee, and Takahiko to demonstrate non-patentability under 35 U.S.C. § 103.
Arista Networks, Inc.vsOrckit Corporation
Arista Networks challenges Orckit Corporation's patent (10652111) in an IPR, asserting that the claimed Deep Packet Inspection functionality within a Software Defined Networking controller is obvious.
Siemens Mobility, Inc. et al.vsMetrom Rail, LLC
Siemens Mobility's IPR challenge against Metrom Rail's rail vehicle control patent was denied by the PTAB. The Board found that the arguments presented were substantially similar to those previously raised during prosecution, leading to a discretionary denial under 35 U.S.C. § 325(d).
ELMOS SEMICONDUCTOR SEvsTexas Instruments Incorporated
ELMOS SEMICONDUCTOR SE's IPR challenge against Texas Instruments Incorporated was denied by the PTAB, as the petitioner failed to demonstrate a reasonable likelihood of prevailing. The Board found that ELMOS lacked adequate motivation and particularity in its obviousness arguments across multiple grounds.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.